Ascendis Pharma A/S (ASND)

Etorro trading 970x250
Ascendis Pharma A/S (ASND) Logo

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, develops therapeutics for unmet medical needs. The company develops TransCon growth hormone, which completed Phase III clinical trials for growth hormone deficiency. It also develops TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for achondroplasia. In addition, the company develops preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark. Address: Tuborg Boulevard 12, Hellerup, Denmark, 2900

Ascendis Pharma A/S News and around…

Latest news about Ascendis Pharma A/S (ASND) common stock and company :

15 Pharmaceutical Stocks to Buy According to Peter Kolchinsky’s RA Capital
25 Nov, 2021 Yahoo! Finance

In this piece, we will take a look at the top 15 pharmaceutical stocks to buy according to Peter Kolchinsky’s RA Capital. If you want to skip our introduction and take a look at the top five stocks in this list, head on over to 5 Pharmaceutical Stocks to Buy According to Peter Kolchinsky’s RA […]

Here’s Why Artisan Partners Increased its Ascendis Pharma (ASND) Position
23 Nov, 2021 Yahoo! Finance

Artisan Partners, a high value-added investment management firm, published its ‘Artisan Mid Cap Fund’ third quarter 2021 investor letter – a copy of which can be downloaded here. A return of 3.06% was recorded by its Investor Class: ARTMX, 3.11% by its Advisor Class: APDMX, and 3.12% by its Institutional Class: APHMX, in the third quarter […]

The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial
19 Nov, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Connect Biopharma Atopic ...

Ascendis' Hypoparathyroidism Candidate Shows Durable Benefit At 84 Weeks
19 Nov, 2021 FinancialContent

Ascendis Pharma A/S(NASDAQ: ASND)announced topline resultsfrom Week 84 of its Phase 2 PaTH Forward Trial of its ...

Ascendis Pharma A/S Announces Top-Line Results from Week 84 of Its Phase 2 PaTH Forward Trial Demonstrating that TransCon™ PTH Provided Durable Benefit and Was Well-Tolerated in Adults with Hypoparathyroidism
18 Nov, 2021 Yahoo! Finance

–– 58 of the original 59 subjects continue in the open-label extension portion of the Phase 2 trial. –– Phase 3 data for TransCon PTH expected in Q1 2022. COPENHAGEN, Denmark, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), today announced top-line results from Week 84 of the Company’s Phase 2 PaTH Forward Trial, a global trial evaluating the safety, tolerability, and efficacy of its investigational TransCon PTH product candidate in adult patients with hypoparathyroidism (H

Ascendis Pharma A/S to Participate in the Evercore ISI 4th Annual HealthCONx Conference
17 Nov, 2021 Yahoo! Finance

COPENHAGEN, Denmark, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company is scheduled to participate in the Evercore ISI 4th Annual HealthCONx Conference. Company executives will participate in a virtual fireside chat hosted by Evercore ISI. Details EventEvercore ISI 4th Annual HealthCONx ConferenceLocationVirtualDateWednesday, December 1, 2021Time3:55-4:15 p.m. Eastern Time A live audio webcast of the presentation will be available on the Invest

Ascendis (ASND) Gets Positive CHMP Opinion for GHD Drug Filing
15 Nov, 2021 Yahoo! Finance

Ascendis Pharma (ASND) is seeking approval for TransCon hGH for the treatment of pediatric growth hormone deficiency in Europe.

Ascendis Pharma A/S - Share Repurchase Program Update
15 Nov, 2021 Yahoo! Finance

COPENHAGEN, Denmark, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided an update on the Company’s previously announced $25 million American Depositary Shares (ADS) Share Repurchase Program. Each ADS represents one ordinary share of Ascendis Pharma A/S. The program was executed under Rules 10b-18 and 10b5-1 of the U.S. securities regulations. Under the program initiated on November 1, 2021, Ascendis Pharma A/S has repurchased shares for an amount up to $25 millio

10 Biggest Price Target Changes For Monday
15 Nov, 2021 FinancialContent

Keybanc boosted the price target on Netflix, Inc. (NASDAQ: NFLX) from $690 to $725. Netflix shares rose 0.2% to $683.90 in ...

Ascendis Pharma A/S Receives Positive CHMP Opinion for TransCon™ hGH for Patients with Pediatric Growth Hormone Deficiency
12 Nov, 2021 Yahoo! Finance

– TransCon hGH is a once-weekly prodrug of somatropin designed to reduce the treatment burden for patients with growth hormone deficiency. – Final European Commission decision on TransCon hGH MAA for pediatric growth hormone deficiency expected within 67 days after positive opinion. COPENHAGEN, Denmark, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positi

Analyst Ratings For Ascendis Pharma
11 Nov, 2021 FinancialContent

Analysts have provided the following ratings for Ascendis Pharma (NASDAQ:ASND) within the last quarter: Bullish Somewhat ...

Ascendis Pharma A/S (ASND) Q3 2021 Earnings Call Transcript
11 Nov, 2021 FinancialContent

ASND earnings call for the period ending September 30, 2021.

Ascendis Pharma A/S Reports Third Quarter 2021 Financial Results
10 Nov, 2021 Yahoo! Finance

– SKYTROFA® (lonapegsomatropin-tcgd) approved by the FDA in the U.S. as a once-weekly treatment for pediatric growth hormone deficiency (GHD); commercially launched in October 2021. – Completed enrollment in Phase 3 PaTHway Trial of TransCon™ PTH. Topline results expected Q1 2022 and 84-week topline results from Phase 2 PaTH Forward Trial expected later this quarter. – Company to hold a virtual R&D update on TransCon PTH, TransCon CNP, and TransCon TLR7/8 Agonist in mid-December to review contin

Were Hedge Funds Right About Ascendis Pharma A/S (ASND)?
10 Nov, 2021 Yahoo! Finance

Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that’s why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]

Ascendis Pharma A/S Presents New Non-Clinical Data for TransCon™ TLR7/8 Agonist Oncology Program at SITC 2021
09 Nov, 2021 Yahoo! Finance

- In non-clinical models, a single dose of TransCon™ TLR7/8 Agonist activated critical innate and adaptive immune mechanisms, providing sustained modulation of tumor microenvironments with low systemic exposure. - Company on track to announce initial monotherapy clinical data for TransCon TLR7/8 Agonist later this quarter. COPENHAGEN, Denmark, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced two poster presentations featuring new non-clinical data for its inve

Ascendis Pharma A/S Announces Third Quarter 2021 Financial Results and Business Update Conference Call on November 10
03 Nov, 2021 Yahoo! Finance

COPENHAGEN, Denmark, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), today announced that the Company will hold a conference call and live webcast on Wednesday, November 10, 2021 at 4:30 p.m. Eastern Time (ET) to review its third quarter 2021 financial results and provide a business update. Conference Call Details DateWednesday, November 10, 2021Time4:30 p.m. Eastern Time/1:30 p.m. Pacific TimeDial In (U.S.)844-290-3904Dial In (International)574-990-1036Access Code2357838 A

Ascendis Pharma Shows Rising Relative Strength; Still Shy Of Key Benchmark
03 Nov, 2021 FinancialContent

Ascendis Pharma shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

This Beaten-Down Biotech Could Rebound Nicely, Says One Fund Manager
26 Oct, 2021 Yahoo! Finance

Ascendis Pharma has a promising treatment for a growth-hormone deficiency. Why a Putnam manager sees "pretty substantial upside."

Ascendis Pharma Breaks Below 200-Day Moving Average - Notable for ASND
25 Oct, 2021 FinancialContent

In trading on Monday, shares of Ascendis Pharma A/S (ASND) crossed below their 200 day moving average of $141.56, changing hands as low as $140.37 per share. Ascendis Pharma A/S shares are currently trading down about 2.8% on the day..

Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2021
20 Oct, 2021 FinancialContent

Upgrades For Iridium Communications Inc (NASDAQ:IRDM), BWS Financial upgraded the previous rating of Neutral to Buy. Iridium ...

Here is What Hedge Funds Think About Ascendis Pharma A/S (ASND)
18 Oct, 2021 Yahoo! Finance

Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don’t make them change their opinion towards a company. This time it may be different. The coronavirus pandemic destroyed the high correlations among major industries and asset classes. We are […]

Ascendis Pharma A/S Announces U.S. Commercial Launch of SKYTROFA® (Lonapegsomatropin-tcgd), the First and Only FDA Approved Once-Weekly Treatment for Pediatric Growth Hormone Deficiency
15 Oct, 2021 Yahoo! Finance

COPENHAGEN, Denmark, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), today announced the U.S. commercial launch of SKYTROFA (lonapegsomatropin-tcgd), its once-weekly treatment for the treatment of pediatric patients one year and older who weigh at least 11.5 kg (25.4 lb) and have growth failure due to inadequate secretion of endogenous growth hormone (GH). SKYTROFA (lonapegsomatropin-tcgd) is available by prescription and distributed through a network of specialty pharmacie

Ascendis Pharma Scores Relative Strength Rating Upgrade; Hits Key Threshold
11 Oct, 2021 FinancialContent

A Relative Strength Rating upgrade for Ascendis Pharma shows improving technical performance.

Ascendis Pharma Sees Relative Strength Rating Climb To 77
07 Oct, 2021 FinancialContent

A Relative Strength Rating upgrade for Ascendis Pharma shows improving technical performance. Will it continue?

This Growth Hormone Drug Could Be a Boost For Pfizer
05 Oct, 2021 FinancialContent

Pfizer and OPKO Health's human growth hormone drug, somatrogon, could be approved by the U.S. Food and Drug Administration next January.

The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs, And More
03 Oct, 2021 FinancialContent

Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Here are the key catalysts that could move stocks in the unfolding week.

The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
03 Oct, 2021 FinancialContent

Biotech stocks came under pressure in the week endingOct. 1, dragged by broader market weakness and the selling ofvaccine ...

Ascendis Pharma A/S Announces Presentations for TransCon™ PTH and TransCon™ CNP at the American Society for Bone & Mineral Research 2021 Annual Meeting
30 Sep, 2021 FinancialContent
Ascendis Pharma A/S Announces Share Repurchase Program
29 Sep, 2021 FinancialContent
Pfizer's Growth Hormone Candidate FDA Review Pushed By 3 Months
27 Sep, 2021 FinancialContent

Pfizer Inc's(NYSE: PFE) effort to defend its growth hormone franchise against a new, more convenient competitor has hit a ...

Ascendis Pharma A/S (ASND) is a NASDAQ Common Stock listed in , ,

970x250